PE Tech Report


Like this article?

Sign up to our free newsletter

VC-backed Invizius awarded major biomedical catalyst grant

Invizius Limited (Invizius), a VC-backed biotechnology company developing treatments to suppress unwanted innate immune responses, has been awarded a GBP1 million grant to bring H-Guard, its proprietary priming solution, designed to reduce the life-threatening inflammatory effects of haemodialysis, to the clinic.

The funds will be used towards H-Guard’s First-in-Man safety study commencing in 2022.
Invizius is supported by a strong syndicate of investors including Mercia, Downing Ventures, Old College Capital, Scottish Enterprise, Solvay Ventures, Calculus Capital and experienced life science entrepreneur and investor, Dr Jonathan Milner. The Company has established the regulatory pathway for H-Guard in North America and the potential for coincident approval in Europe.

Like this article? Sign up to our free newsletter